SEC Form 8-K Summary
Registrant: Tivic Health Systems, Inc. The request metadata identifies Valion Bio, Inc., but the filing names Tivic Health Systems, Inc. as the registrant.
Report date: July 31, 2023. The filing is a Regulation FD disclosure under Item 7.01 and does not report quarterly or annual financial results.
Business Context and Filing Event
The company announced that the U.S. Patent and Trademark Office issued a new patent covering certain elements of its bioelectronic platform. The related press release was furnished as Exhibit 99.1. The filing text provided does not include the patent number, expiration date, claims, commercial scope, or expected financial impact.
Financial Metrics and Capitalization
- Revenue, net income, operating income, cash flow, margins, debt, cash balances, liquidity, and other financial metrics are not provided in this filing.
- No financial statements are included.
- The company’s common stock trades on Nasdaq under the symbol TIVC.
Material Changes Versus Prior Period
The filing does not provide comparative-period information or quantify any change in operating or financial performance. The disclosed development is the issuance of the new patent.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance or specific operating outlook is provided.
- The filing includes customary forward-looking statement language and cautions that actual results may differ materially because of known and unknown risks and uncertainties.
- The filing does not quantify the patent’s expected effect on commercialization, revenue, expenses, cash needs, or competitive position.
- The Item 7.01 information and Exhibit 99.1 are furnished, not filed, and are generally not subject to Section 18 liability or incorporated by reference into other filings unless expressly stated.
Investor Verification Items
- Confirm the correct issuer: the filing is for Tivic Health Systems, Inc., not Valion Bio, Inc.
- Review Exhibit 99.1 for the patent number, technology covered, ownership, term, and any commercialization claims.
- Assess whether the patent provides meaningful protection for current or planned products and whether third-party rights or litigation risks exist.
- Consult the company’s latest periodic report for cash, liquidity, debt, operating losses, revenue trends, and going-concern or financing disclosures.
- Verify subsequent filings for any additional patent, product, financing, or business updates.